DFTX
Definium·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DFTX
Definium Therapeutics, Inc.
A clinical stage neuropharmaceutical development company
One World Trade Center, Suite 8500, New York, New York 10007
--
Definium Therapeutics, Inc., is incorporated in Canada. They are a clinical-stage neurodrug development company that develops psychedelic-based drug candidates through rigorous scientific and clinical trials. Their mission is to discover, develop and deploy psychedelic-inspired drugs and therapies to treat psychiatry, neurology, addiction, pain, and potentially other disorders such as anxiety, substance abuse and withdrawal, and adult attention deficit disorder.
Company Financials
EPS
DFTX has released its 2025 Q3 earnings. EPS was reported at -0.78, versus the expected -0.5, missing expectations. The chart below visualizes how DFTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
